Inotuzumab ozogamicin 治疗成人急性淋巴细胞白血病：发展、现状和未来方向。
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
发表日期：2024 Aug 02
作者：
Hagop M Kantarjian, Nicolas Boissel, Cristina Papayannidis, Marlise R Luskin, Matthias Stelljes, Anjali S Advani, Elias J Jabbour, Josep-Maria Ribera, David I Marks
来源：
CANCER
摘要：
Inotuzumab ozogamicin (InO) 是一种抗体药物偶联物，被批准用于治疗复发/难治性 B 细胞急性淋巴细胞白血病 (ALL)。几项临床试验正在研究 InO 与低强度化疗或其他抗 ALL 靶向治疗相结合，用于抢救和一线治疗，特别是在经常无法耐受强化化疗且往往患有较高风险疾病的老年人中。 InO 也越来越多地用于为患者与造血干细胞移植 (HSCT) 建立桥梁，并与嵌合抗原受体 T 细胞疗法依次进行，以消除可测量的残留疾病并防止 HSCT 后复发。静脉闭塞性疾病/正弦波阻塞综合征是 InO 治疗的潜在并发症，特别是在随后进行 HSCT 时。在此，作者回顾了 InO 的历史发展和现状、降低 InO 相关静脉闭塞性疾病/正弦阻塞综合征风险的策略，以及 InO 研究和临床使用的未来方向。© 2024 美国癌症协会。
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). Several clinical trials are investigating InO in combination with low-intensity chemotherapy or other anti-ALL-targeted therapies in the salvage and frontline settings, notably in older adults who often cannot tolerate intensive chemotherapy and tend to have higher-risk disease. InO is also increasingly used to bridge patients to hematopoietic stem cell transplantation (HSCT), in sequence with chimeric antigen receptor T-cell therapy, to eliminate measurable residual disease and to prevent post-HSCT relapse. Veno-occlusive disease/sinusoidal obstruction syndrome is a potential complication of InO treatment, particularly when followed by HSCT. Herein, the authors review the historical development and current status of InO, strategies for mitigating the risk of InO-related veno-occlusive disease/sinusoidal obstruction syndrome, and future directions for InO research and clinical use.© 2024 American Cancer Society.